Risk Factors and Prognosis of New-Onset Chronic Kidney Disease Following Orthotopic Liver Transplantation: A Retrospective Case-Control Study

BCD 1 Yi Duan*
EF 2 Zuozhi Li*
BF 1 Xiaoyu Wang*
B 1 Lei Cui
A 1 Zhifeng Gao
A 1 Huan Zhang

* Yi Duan, Zuozhi Li and Xiaoyu Wang are co-first authors

Corresponding Authors: Zhifeng Gao, e-mail: sunshine_duan@163.com, Huan Zhang, e-mail: zha00558@btch.edu.cn

Financial support: Departmental sources

Background: We have undertaken this investigation to explore the perioperative risk factors of new-onset chronic kidney disease (NOCKD) after orthotopic liver transplantation (OLT), and to provide an early prediction model for the screening of NOCKD high-risk populations.

Material/Methods: A retrospective case-control study was performed in adult recipients who received OLT in our center between January 2018 and January 2020. Perioperative data were collected using the center’s electronic medical record system. Logistic regression analysis was used to determine risk factors for NOCKD within 1 year following OLT. Kaplan-Meier and log-rank tests were used to evaluate the 1-year survival of recipients with NOCKD or without NOCKD.

Results: A total of 174 patients were included in this study, and 29 patients developed NOCKD after OLT. Logistic multivariate regression analysis showed that preoperative diabetes, high model for end-stage liver disease (MELD) score, postoperative acute kidney injury (AKI), and postoperative renal replacement therapy (RRT) were independent risk factors for NOCKD 1 year after OLT. The 1-year survival rate of NOCKD recipients was significantly lower than that of patients who did not receive NOCKD.

Conclusions: Diabetes mellitus, MELD score, postoperative AKI, and requirement for postoperative RRT are independent risk factors for NOCKD after OLT, which may have great potential for personalized decision making and predicting the 1-year postoperative mortality of the recipient.

Keywords: Diabetes Mellitus • Liver Transplantation • Renal Insufficiency, Chronic

Abbreviations: NOCKD – new-onset chronic kidney disease; OLT – orthotopic liver transplantation; MELD – model for end-stage liver disease; AKI – acute kidney injury; RRT – renal replacement therapy; CKD – chronic kidney disease; ESRD – end-stage renal disease; CNI – calcineurin inhibitors; eGFR – estimated glomerular filtration rate; KDIGO – Kidney Disease Improvement Global Outcomes Organization; ICA – International Club of ASCITES; sCr – serum creatinine; HIS – hospital information system; BMI – body mass index; INR – international normalized ratio; SD – standard deviation; QR – interquartile range; ROC – receiver operator characteristic

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/931834
Background

Chronic kidney disease (CKD) is a global public health issue, which also widely occurs among transplant recipients. Convincing evidence suggests that a large number of recipients experience renal function decline after organ transplantation [1], and a considerable number of them will progress to CKD [2]. The incidence of CKD within 1 year after orthotopic liver transplantation (OLT) is 4.0% to 27.5% [3], second only to the rates in heart and lung transplantation recipients. CKD may further develop into end-stage renal disease (ESRD), requiring several years of renal replacement therapy (RRT) or even kidney transplantation, which causes a heavy social and economic burden [4] and adversely impacts quality of life. In addition, CKD is associated with an increased incidence of cardiovascular events following transplantation and leads to increased readmission and mortality risk [5]. Thus, there is an urgent need for analysis and insight into the causes of and a potential prediction model for CKD after OLT [6-8].

Previous studies suggested that age, female, hypertension, diabetes, model for end-stage liver disease (MELD) score, preoperative glomerular filtration rate, hemoglobin levels, and duration of renal impairment are correlated with the onset and progression of CKD in patients with cirrhosis [9-12]. However, the risk factors and their effects on CKD remain controversial. Moreover, most previous studies focused on transplant recipients with preoperative renal dysfunction. Postoperative CKD may be attributable to preoperative renal parenchymal injury. Nevertheless, little is known about perioperative risk factors for NOCKD in patients without CKD prior to OLT. Defining the risk factors for NOCKD after OLT may facilitate early identification of potential high-risk groups, help personalize perioperative anesthetic management, and avoid the use of nephrotoxic drugs such as calcineurin inhibitors (CNI) in postoperative treatment [8,13], so as to improve prognosis and short- and long-term survival rates. Moreover, in Asian countries there are no available prediction models that can identify patients at increased risk of NOCKD and related poor prognosis after OLT based only on their perioperative characteristics. This study aimed to retrospectively analyze the perioperative characteristics in patients with CKD after OLT in adults with preoperative estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m², and to provide an early prediction model for the screening of NOCKD high-risk groups.

Material and Methods

Study Design and Population

This single-center, retrospective study included all consecutive adult patients who underwent LT between 1 January 2018 and 1 February 2020. All recipients were tested for serum creatinine levels and assessed for eGFR prior to transplantation, 1 to 7 days after transplantation, and 1, 3, 6, 9, and 12 months after transplantation, according to the conventional treatment strategy. Patients who underwent the following procedures were excluded: (1) Patients under 18 years of age, (2) Renal replacement treatment before OLT or baseline eGFR <60 ml/(min·1.73·m²), (3) Survival less than 3 months, (4) Lack of important data, (5) Surgery cancelled after anesthesia. The requirement for informed consent was waived for this study.

Diagnostic Criteria for Acute Kidney Injury (AKI) and NOCKD

According to the revised definition of AKI in patients with cirrhosis by the Kidney Disease Improvement Global Outcomes Organization (KDIGO) [14] and the recommendation of the International Club of Ascites (ICA) [15], AKI is defined as increase in serum creatinine (sCr) by ≥26.4 μmol/L (0.3 mg/dL) in <48 h or 50% increase in sCr from baseline, which is known or presumed to have occurred within the prior 7 days (the baseline value refers to the stable value within 3 months before surgery. If not available, the measured value at admission was used. Stage 1 refers to sCr increase 1.5-1.9 times baseline, or Cr increase ≥0.3 mg/dl (26.5 μmol/L); stage 2 refers to sCr increase 2.0-2.9 times baseline; and stage 3 refers to sCr increase 3.0 times baseline, or sCr increase to ≥4.0 mg/dl (353.6 μmol/L), or initiation of renal replacement therapy.

According to the 2012 KDIGO [16] guideline for the diagnosis and management of adults and children with CKD, the diagnostic criteria for CKD is eGFR <60 ml/(min·1.73·m²) for >3 months. In this study, NOCKD was defined as the diagnosis of CKD after OLT in patients with preoperative eGFR ≥60 ml/(min·1.73·m²).

Immunosuppressive Management

Methylprednisolone was administered in a 500-mg intravenous bolus 30 min before graft reperfusion. Following liver transplantation, patients were maintained on MMF-, tacrolimus-, and prednisone-based immunosuppressive therapy. The tacrolimus concentration was maintained at 8-10 ng/ml for 3 months after the operation. MMF was administrated at 0.5 g b.i.d. in the first 3 months and then reduced to 0.25 g. MMF was slowly discontinued at 6 months after transplantation. Methylprednisolone was administered orally at 240 mg, reduced by 40 mg daily until reduced to 40 mg daily. Then, methylprednisolone was changed to oral prednisolone 20 mg daily, reduced by 2.5 mg weekly until reduced to 5 mg and maintained for 1 month, and stopped thereafter.
In patients with hepatitis C or malignant tumors, tacrolimus trough levels were maintained at 6–8 ng/ml within 3 months after the operation. MMF was administered at 0.5 g b.i.d. until the end of the third month. Prednisone was reduced by 5 mg weekly for 1 month, and stopped thereafter.

For patients with renal insufficiency after transplantation, 20 mg Basiliximab was administered on post-transplant day 1 and day 4, without CNI administration. If the arterial condition was good, rapamycin (a mTOR inhibitor) was given orally at the dose of 2 mg per day 1 week after surgery. If the arterial condition was poor, MMF was used alone and increased to 1 g every 12 h, and then gradually changed to rapamycin or rapamycin combined with MMF 1 month after liver transplantation.

Data Collection
The following data were collected through the outpatient or inpatient electronic medical records of the Hospital Information System (HIS), the Docare Anesthesia Clinical Information System (V5.0) and follow-up visits:

Preoperative basic information: recipient age, sex, body mass index (BMI), MELD score, complications including acute liver failure, ascites, diabetes mellitus, hypertension, and coronary heart disease, as well as type of the primary disease (eg, post-hepatitis B cirrhosis, post-hepatitis C cirrhosis, alcoholic cirrhosis and non-alcoholic fatty liver disease, liver hydatid disease, liver cancer), preoperative hemoglobin level, preoperative albumin level, preoperative total bilirubin level, preoperative glutation-pyruvic transaminase level, preoperative sCr, preoperative international normalized ratio (INR), preoperative serum sodium levels, donor age, and warm and cold ischemia time.

Intraoperative and anesthetic information included operation duration, portal vein occlusion time, amount of crystal fluid infusion, 5% albumin infusion, red blood cell infusion, fresh frozen plasma infusion, blood loss, urine volume, norepinephrine dosage, and duration of intraoperative minimum blood pressure.

Postoperative outcome information included postoperative anti-rejection treatment, incidence and severity of AKI, rate of postoperative RRT, length of postoperative ICU stay, postoperative hospital stay, postoperative incidence of CKD within 1 year, and postoperative cause of death and mortality within 1 year.

Follow-Up
Patients were followed and events recorded until 31 January 2021 and/or death.

Statistical Analysis
Data were analyzed using SPSS 26.0 statistical software. Normally distributed data were expressed as mean±standard deviation (SD) and compared by independent-sample t test, while nonnormally distributed data were expressed as median and interquartile range (IQR) and compared by Mann-Whitney U test. Categorical data were analyzed using chi-square test or Fisher’s exact test. Risk factors were analyzed by binary logistic regression analysis. The receiver operator characteristic (ROC) curve was used to analyze the model performance. Survival analysis was performed using Kaplan-Meier and log-rank tests. P<0.05 was considered statistically significant.

Ethics
The study was approved by the Beijing Tsinghua Changgung Hospital Ethics Committee (approval number: 21017-6-01) and the requirement the informed consent was waived by Beijing Tsinghua Changgung Hospital Ethics Committee. Our study was carried out in accordance with the Declaration of Helsinki (2013) of the World Medical Association and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for human observational studies.

Results
A total of 235 patients who underwent orthotopic allogeneic OLT in our center were included in the study. Among them, 3 recipients were younger than 18 years old, 38 recipients received preoperative renal replacement therapy or preoperative eGFR <60 mL/(min·1.73·m^2), 16 recipients died within 3 months after surgery, 3 recipients had incomplete case information, and 1 recipient cancelled the OLT. A total of 174 patients were included in the study for data analysis (Figure 1). We identified 54 patients (31.0%) who developed AKI within 1 week after surgery, with stage 1 in 19 patients, stage 2 in 3 patients, and stage 3 in 15 patients. In this study, a total of 29 (16.7%) recipients developed NOCKD after OLT.

Recipients were divided into a NOCKD group and a non-CKD group according to whether they were diagnosed with NOCKD after surgery. Univariate analysis showed that the preoperative prevalence of diabetes was higher in the NOCKD group (55.2% vs 15.2%, P<0.01) and the preoperative hemoglobin level was lower in the NOCKD group (96.8±27.51 g/L vs 111.64±25.78 g/L, P<0.01). The preoperative MELD score was higher in the NOCKD group (21.14±12.69 vs 12.75±6.03, P<0.01). The NOCKD group had higher volumes of infused fresh frozen plasma (FFP) during surgery [600 (400, 800) ml vs 400 (0, 700) ml, P<0.01, Table 1].
235 patients undergoing OLT between January 2018 and February 2020

Excluded criteria:
- Patients under 18 years of age (n=3)
- Renal replacement treatment before OLT or baseline eGFR <90 ml/(min·1.73·m²) (m=38)
- Survival less than 3 months (n=16)
- Lack of important data (n=3)
- Surgery cancelled after anesthesia (n=1)

174 patients undergoing OLT included in final analyses

Diagnostic criteria of post-OLT CKD (KDIGO):
eGFR <60 ml/(min·1.73·m²) for 3 months, regardless of the presence or absence of structural kidney damage

Table 1. Demographic and characteristics of the 174 patients, stratified by NOCKD.

| Variable                  | NOCKD (n=29) | non-CKD (n=145) | Z/t/χ² | P value |
|---------------------------|--------------|-----------------|--------|---------|
| Patients' characteristics |              |                 |        |         |
| Age (±s, yr)              | 49.38±12.76  | 52.14±10.16     | -1.280 | 0.202   |
| Gender (Male) [n (%)]     | 19 (65.5)    | 117 (80.7)      | 3.259  | 0.071   |
| BMI (±s, kg/m²)           | 24.06±3.63   | 23.79±3.80      | 0.350  | 0.727   |
| MELD score (±s)           | 21.14±12.69  | 12.75±6.03      | 5.466  | 0.000   |
| Ascites [n (%)]           | 16 (55.2)    | 68 (46.9)       | 0.663  | 0.416   |
| Diabetes mellitus [n (%)] | 16 (55.2)    | 22 (15.2)       | 22.652 | 0.000   |
| Hypertension [n (%)]      | 2 (10.5)     | 27 (18.6)       | 2.392  | 0.122   |
| Etiology                 |              |                 |        |         |
| HBV [n (%)]               | 16 (55.2)    | 79 (54.5)       | 0.005  | 0.946   |
| HCV [n (%)]               | 0 (0)        | 7 (4.8)         | 1.459  | 0.227   |
| Alcoholic cirrhosis [n (%)]| 2 (10.5)    | 11 (7.6)        | 0.017  | 0.897   |
| Other cirrhosis [n (%)]   | 5 (17.2)     | 18 (12.4)       | 0.491  | 0.483   |
| Hepatic echinococcosis [n (%)]| 0 (0)    | 6 (4.1)         | 1.243  | 0.265   |
| Hepatocellular carcinoma [n (%)]| 13 (44.8) | 77 (53.1)       | 0.663  | 0.416   |
| Other chronic liver diseases [n (%)]| 0 (0) | 1 (0.6)         | 0.203  | 0.653   |
| Preoperative laboratory data |              |                 |        |         |
| Baseline hemoglobin (±s, g/L) | 96.83±27.51 | 111.64±25.78    | -2.792 | 0.006   |
| Baseline albumin (±s, g/L)  | 32.69±5.31   | 35.94±8.41      | -1.963 | 0.051   |
| Baseline ALT [M(IQR), U/L] | 31.8 (21.75, 53.1) | 29.8 (20.2, 52.7) | 0.175 | 0.861   |

Figure 1. Flow chart of patient selection. OLT – orthotopic liver transplantation; eGFR – estimated glomerular filtration rate; KDIGO – Kidney Disease of Improving Global Outcomes; NOCKD – new-onset chronic kidney disease; CKD – chronic kidney disease.
Table 1 continued. Demographic and characteristics of the 174 patients, stratified by NOCKD.

| Variable                              | NOCKD (n=29) | Non-CKD (n=145) | Z/t/c2 | P value |
|---------------------------------------|--------------|-----------------|--------|---------|
| Baseline sCr (\(\bar{x} \pm s, \mu mol/L\)) | 62.13±41.61  | 65.63±21.60     | -0.656 | 0.513   |
| Baseline Sodium (\(\bar{x} \pm s, mmol/L\)) | 137.65±5.38  | 136.74±16.84    | 0.282  | 0.778   |

Donor data

| Variable                      | NOCKD (n=29) | Non-CKD (n=145) | Z/t/c2 | P value |
|-------------------------------|--------------|-----------------|--------|---------|
| Donor age (\(\bar{x} \pm s, yr\)) | 49.45±11.88  | 50.68±10.53     | -0.560 | 0.576   |
| WIT [M(IQR), s]               | 361 (55, 432) | 313 (5, 431)    | 0.095  | 0.621   |
| CIT (\(\bar{x} \pm s, minutes\)) | 443.76±151.79 | 417.70±149.06  | 0.857  | 0.393   |

Intraoperative data

| Variable                                | NOCKD (n=29) | Non-CKD (n=145) | Z/t/c2 | P value |
|-----------------------------------------|--------------|-----------------|--------|---------|
| Operation duration (\(\bar{x} \pm s, h\)) | 9.87±1.84    | 9.85±2.71       | 0.056  | 0.956   |
| Anhepatic phase (\(\bar{x} \pm s, minutes\)) | 80.45±31.19  | 77.10±43.96     | 0.390  | 0.697   |
| Crystalloids (\(\bar{x} \pm s, ml\))   | 3723.28±1547.14 | 4180.77±1762.86 | -1.299 | 0.196   |
| 5% albumin (\(\bar{x} \pm s, ml\))     | 2884.48±1362.71 | 2922.32±1325.27 | -0.139 | 0.889   |
| RBC [M(IQR), U]                        | 8 (4,10)     | 4 (2.9,25)      | 1.154  | 0.248   |
| FFP [M(IQR), ml]                       | 600 (400,800) | 400 (0,700)     | 3.049  | 0.002   |
| Blood loss (\(\bar{x} \pm s, ml\))    | 1224.14±959.09  | 1311.46±1096.51 | -0.402 | 0.688   |
| Urine output (\(\bar{x} \pm s, ml\))  | 2140.52±1355.67 | 2219.28±1135.98 | -0.330 | 0.742   |
| Norepinephrine [M(IQR), ug]            | 691.50 (181.72, 2848.30) | 843.75 (164.35, 2288.90) | 0.387  | 0.699   |
| Hypotension duration (\(\bar{x} \pm s, min\)) | 27.24±13.77  | 22.36±10.71     | 2.127  | 0.035   |

BMI – body mass index; MELD – model of end-stage liver disease; HBV – hepatitis B virus; HCV – hepatitis C virus; ALT – alanine aminotransferase; sCr – serum creatinine; WIT – warm ischemia time; CIT – cold ischemia time; RBC – red blood cells; FFP – fresh frozen plasma; the definition of hypotension: systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg

Table 2. Postoperative outcomes of patient with or without NOCKD.

| Variables                      | NOCKD (n=29) | Non-CKD (n=145) | Z/t/c2 | P value |
|-------------------------------|--------------|-----------------|--------|---------|
| Overall AKI [n (%)]            | 22 (75.9)    | 32 (22.1)       | 32.673 | 0.000   |
| AKI stage 1 [n (%)]            | 3 (10.3)     | 16 (11.0)       | 0.012  | 0.913   |
| AKI stage 2 [n (%)]            | 6 (20.7)     | 11 (7.6)        | 4.707  | 0.030   |
| AKI stage 3 [n (%)]            | 13 (44.8)    | 5 (3.4)         | 44.615 | 0.000   |
| Postoperative RRT [n (%)]      | 11 (37.9)    | 3 (2.1)         | 42.009 | 0.000   |
| ICU stay [M(IQR), d]           | 3 (2,5)      | 3 (2,4)         | 0.678  | 0.498   |
| Postoperative hospitalization [M(IQR), d] | 24 (19.0, 30.5) | 21.0 (17.0, 26.75) | 1.660  | 0.097   |

AKI – acute kidney injury; RRT – renal replacement therapy; ICU – Intensive Care Unit.
No immnosuppressant toxicity-related AKI was observed in NOCKD group and non-CKD group. The incidence of AKI in the NOCKD group was higher than that in the non-CKD group within 1 week after OLT (75.9% vs 22.1%, \( P < 0.01 \)). The incidence of stage 2 and stage 3 AKI in the NOCKD group was also significantly higher (\( P < 0.01 \)). In addition, patients in the NOCKD group had higher demand for RRT after transplantation than the non-CKD group (25% vs 2.2%, \( P < 0.01 \), Table 2).

Associations between variables and NOCKD were visualized using a heatmap (Figure 2), which illustrated that diabetes, MELD score, baseline hemoglobin, baseline albumin, fresh frozen plasma (FFP), postoperative AKI, and postoperative RRT were factors correlated with NOCKD.

The results of regression analyses are shown in Table 3. Preoperative diabetes, MELD score, postoperative AKI, and postoperative RRT were independent risk factors for NOCKD. A prediction model containing the 4 variables was developed using multivariable logistic regression analyses. The formula of the original model was: 

\[
R = -3.616 + 1.188 \times (\text{diabetes}) + 0.084 \times (\text{preoperative MELD score}) + 1.269 \times (\text{postoperative AKI}) + 2.524 \times (\text{postoperative RRT}).
\]

\( R \) was divided by 0.084 to obtain the predictive factor \( R_1 \):

\[
R_1 = (\text{preoperative MELD score}) - 43 + 14 (\text{if preoperative diabetes}) + 15 (\text{if postoperative AKI}) + 30 (\text{if postoperative RRT required})\].

The ROC curve was further obtained (Figure 3A, AUC: 0.879, 95% CI: 0.802–0.957). The lower the value of \( R_1 \), the lower the risk of NOCKD within 1 year after surgery. The cut-off value was -17 (Figure 3B).

There were 174 recipients followed up for 6-34 months, and the median follow-up duration was 21 months. A total of 150 patients were followed up for 1 year, and the 1-year survival rate was E931834-6

---

**Table 3.** Logistic regression analysis of patients with or without NOCKD.

| Variables               | b     | OR   | \( P \) value | 95% CI            |
|-------------------------|-------|------|---------------|-------------------|
| Diabetes mellitus       | 1.188 | 3.280| 0.045         | 1.025–10.491     |
| MELD score              | 0.084 | 1.088| 0.012         | 1.019–1.162      |
| Baseline hemoglobin     | -0.0001 | 0.999 | 0.959         | 0.974–1.025      |
| Baseline albumin        | -0.017 | 0.983 | 0.680         | 0.905–1.067      |
| FFP                     | 0.000 | 1.000| 0.806         | 0.998–1.001      |
| Postoperative AKI       | 1.269 | 3.557| 0.048         | 1.013–12.489     |
| Postoperative RRT       | 2.524 | 12.478| 0.003         | 2.324–66.990     |

FFP – fresh frozen plasma; AKI – acute kidney injury.

---

Figure 2. The heatmap of correlations between NOCKD and correlated factors. Correlation coefficients are shown. Diabetes, MELD score, baseline hemoglobin, baseline albumin, fresh frozen plasma (FFP), postoperative AKI, and postoperative RRT were factors correlated with NOCKD (\( P \) all <0.05).

Figure 3. The ROC curve of predictive model.
rate was 96.0%. During the follow-up, 6 patients died, among which 3 patients had multiple organ failure, 2 patients had respiratory complications, and 1 patient had cerebral hemorrhage. Log-rank survival statistics showed that the 1-year survival rate in the NOCKD group was significantly lower than that in the non-CKD group (88.9% vs 97.6%, \( P = 0.036 \), Figure 4A). Moreover, a similar 1-year survival pattern was observed when stratified by R1, suggesting that R1 \( \leq -17 \) may be a promising predictive tool to help provide early prevention of NOCKD (90.2% vs 99.0%, \( P = 0.01 \), Figure 4B).

**Discussion**

The creatinine-based KDIGO criteria are widely used to define CKD after OLT, which takes the eGFR of less than 60 ml/min\( \cdot \)1.73\( \cdot m^2 \) for more than 3 months as the diagnostic criterion [16]. Previous studies have shown that the incidence of CKD after OLT ranges from 17.1% to 40.9% [17-20]. One of the reasons for the large difference in the incidence of CKD in different studies may be related to the length of follow-up, as the incidence increased with the time after OLT [8,21,22]. We observed that the incidence of CKD 1 year after OLT was 17.1%, which was relatively low compared to some previous studies. There are a few possible reasons for this. First, kidney injury prior to OLT is a significant predictor of postoperative CKD. Maurel et al demonstrated that the HR for predicting postoperative CKD with PCRS was 2.5 (95%CI: 1.2-4.9) [23]. To rule out the confounding interference of preoperative renal insufficiency or decompensation, the current study included patients without preoperative CKD. In the present study, we included patients with preoperative eGFR \( \geq 60 \) ml/min/1.73m\(^2\), so that...
the potential interference of preoperative renal insufficiency or decompensation was eliminated from the data as much as possible. As a result, the incidence of postoperative CKD was lower than that obtained from the general population. Second, previous studies demonstrated that the administration of calcineurin inhibitors (CNI), a type of anti-rejection drug, is an independent risk factor for CKD after OLT [24,25]. Indeed, CNI drugs such as tacrolimus and cyclosporine A are the most common nephrotoxic drugs [26,27]. However, the risk of kidney injury was significantly lower in patients treated with the combination of tacrolimus and mycophenolate mofetil (MMF) [28]. In addition, reducing the dose of CNI used through combination therapy may effectively reduce the incidence of AKI and CKD without increasing the risk of rejection [29-31]. A combination of MMF, glucocorticoid, and CNI was used in our center to prevent rejection after OLT, and the dose was adjusted according to blood concentration, which was one of the possible reasons for the decrease of NOCKD incidence after OLT.

Notably, postoperative AKI or acute renal failure after OLT is associated with increased in-hospital mortality. The degree of AKI can be alleviated or worsened by treatment. It is worth paying attention to whether the renal parenchyma injury of the recipient after OLT will affect the long-term survival rate. In this study, the postoperative follow-up showed that the 1-year mortality rate of NOCKD recipients was significantly higher than that of non-NOCKD recipients, suggesting that chronic renal function injury is of great value in predicting the medium and long-term survival of OLT patients.

The incidence of chronic kidney disease after OLT is affected by multiple factors. This study demonstrated that preoperative diabetes, MELD score, and postoperative AKI requirement for RRT were independent risk factors for NOCKD after the transplantation.

In recent years, the prevalence of type 2 diabetes has increased significantly, and patients with end-stage liver disease are more likely to be complicated with glucose metabolism disorders. Previous studies indicated that diabetes is related to the onset and development of CKD [32]. Lee et al showed that preoperative diabetes was an independent risk factor for the development of CKD within 10 years after OLT [33]. In this study, the prevalence of preoperative diabetes in the 174 recipients was 21.8%. In line with our data, Bassegoda et al [2] showed a similar result. The preoperative prevalence of diabetes in the NOCKD group was 55.2%, which was significantly higher than that in the non-CKD group. After multivariate regression analysis, there was still a significant correlation with CKD 1 year after surgery (OR 3.280, 95%CI 1.025-10.491). These data suggest that preoperative diabetes screening is crucial for OLT recipients. Future studies should focus on the effect of preoperative blood glucose management on renal function following OLT.

MELD score, one of the main guiding criteria for organ allocation in OLT, is a scoring system for evaluating the severity and prognosis of end-stage liver disease in patients over 12 years old. High MELD score predicts worse liver function, which is associated with impaired renal function. Previous studies have reported that high preoperative MELD score is correlated with an increased risk of CKD after OLT [17]. In the current study, the MELD score of the NOCKD group was 21.14±12.69, significantly higher than that of the non-CKD group, indicating that MELD score is an independent risk factor for CKD 1 year after transplantation. Thus, for patients with a high preoperative MELD score, there is an urgent need for enhanced renal protection during perioperative anesthesia management and postoperative immunotherapy.

AKI is a common complication after OLT [34]. In this study, the incidence of AKI in the NOCKD group was 75.9%, significantly higher than that in the non-AKI group (22.1%). AKI can lead to irreversible renal damage and progression to CKD. Peng et al reported that AKI (OR=1.496, $P<0.01$) was significantly associated with the occurrence of CKD [17]. Trinh et al [35] showed that AKI was associated with a doubling of the incidence of CKD. Octavi et al [2] demonstrated that in a total of 409 patients with cirrhosis, about 25% of those with AKI progressed to CKD. Furthermore, the transition from AKI to CKD was associated with the severity of AKI. Therefore, timely prevention of postoperative AKI is crucial, emphasizing the importance of earlier detection and identification of individuals at high risk for AKI following OLT.

In the present study, 174 patients had eGFR ≥60 ml/min/1.73 m² before surgery, among which 14 patients underwent RRT due to stage 3 postoperative AKI. Intriguingly, 37.9% of NOCKD patients required RRT, while only 2.1% of patients without postoperative NOCKD received RRT therapies (Table 2). RRT is an effective procedure for the treatment of severe AKI [36], particularly in patients with acute and correctable etiology. Early initiation of RRT in critically ill patients improves renal functional outcomes [37,38]. Unfortunately, most previous studies excluded patients with preoperative cirrhosis and hepatorenal syndrome, which are common complications in patients undergoing OLT. As a result, there is a lack of robust evidence about RRT strategy for renal insufficiency after OLT. Gaudry et al [39] reported that the survival rate of critically ill patients with severe AKI but no urgent indications for RRT does not correlate with the timing of RRT initiation. Safwan et al [40] proposed that RRT did not improve the prognosis of OLT recipients when it was used as an urgent treatment for new-onset AKI. The constellation of these data indicates that it is necessary to carefully evaluate the effect of postoperative RRT on CKD, to determine the timing of RRT initiation, and to further improve the RRT therapeutic strategy after OLT.
**Limitations**

There are several limitations to the present study. First, this was a single-center study, so bias may exist due to lack of data from other centers. Second, the sample size of this study was relatively small. With the development of the transplantation center in our hospital, more patients can be included in future studies. Third, the median length of follow-up was 21 months, which was relatively short. Our further studies will extend the follow-up period and continue to observe the incidence of CKD at 3 and 5 years postoperatively, as well as the outcomes of CKD. Finally, the prediction model in this study should be validated in future prospective studies.

**Conclusions**

In conclusion, diabetes mellitus, MELD score, postoperative AKI, and requirement for postoperative RRT are independent risk factors for NOCKD in OLT recipients, which may be clinically significant to predict 1-year postoperative mortality. The model established in this study may facilitate early identification of the high-risk population of NOCKD after OLT, establishment of perioperative renal protection strategy, evidence for early reduction or cessation of immunosuppressive agents with nephrotoxicity, and improvement of prognosis.

**References:**

1. Herrero JL, Cuervas-Mons V, Gómez-Bravo MA, et al. Prevalence and progression of chronic kidney disease after liver transplant: A prospective, real-life, observational, two-year multicenter study. Rev Esp Enferm Dig. 2018;110(9):538-43
2. Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impair clinical outcomes. J Hepatol. 2020;72(6):1132-39
3. Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: Evaluation of the critical issues. Liver Transpl. 2012;18(11):1290-301
4. von Zur-Mühlen B, Wintzel V, Levine A, et al. Healthcare resource use, cost, and sick leave following kidney transplantation in Sweden: A population-based, 5-year, retrospective study of outcomes. COIN. Ann Transplant. 2018;23:852-66
5. Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):59-73.
6. Allen AM, Kim WR, Thneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation – a time-dependent analysis using measured glomerular filtration rate. J Hepatol. 2014;61(2):286-92
7. Longenecker JC, Estrella MM, Segev DL, Atta MG. Patterns of kidney function before and after orthotopic liver transplant: Associations with length of hospital stay, progression to end-stage renal disease, and mortality. Transplantation. 2015;99(12):2556-64
8. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-40
9. Ruebner R, Goldberg D, Abt PL, et al. Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction. Am J Transplant. 2012;12(11):2958-65
10. Israni AK, Xiong H, Liu J, et al. Predicting end-stage renal disease after liver transplant. Am J Transplant. 2013;13(7):1782-92
11. Sharma P, Goodrich NP, Schaubel DE, et al. Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol. 2013;24(12):2045-52
12. Maiwall R, Pasupuleti SSR, Bhari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: A prospective cohort study. Hepatology. 2020;71(3):1009-22
13. O’Leary JG, Levitsky J, Wong F, et al. Protecting the kidney in liver transplant candidates: Practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516-31
14. Jagarlamudi N, Wong F. Acute kidney injury: Prediction, prognostication and optimisation for liver transplant. Hepatol Int. 2020;14(2):167-79
15. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis. Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-74
16. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30
17. Peng IC, Li Y, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24(9):806-12
18. Gojowy D, Kubis P, Gorecka M, et al. Chronic kidney disease in patients after liver transplantation: A long-term retrospective analysis from 1 transplantation center. Transplant Proc. 2020;52(8):2492-96
19. Li Y, Li B, Wang W, Lv J. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant. Exp Ther Med. 2018;15(4):3589-95
20. Menon S, Pollack AH, Sullivan E, et al. Acute kidney injury and chronic kidney disease after non-kidney solid organ transplantation. Pediatr Transplant. 2020;24(6):e13753

**Ethics Approval and Consent to Participate**

The study was approved by the Beijing Tsinghua Changgung Hospital Ethics Committee (Approval Number: 21017-6-01) and the requirement for informed consent was waived by the Beijing Tsinghua Changgung Hospital Ethics Committee.

**Trial Registration**

Our study is registered in the Chinese Clinical Trial Registry (ChiCTR, ChiCTR2100042542).

**Conflict of Interests**

None.

**Declaration of Figures Authenticity**

All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.
21. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation. 2001;72(12):1934-39

22. Ye L, Zhang Y, Tang H, et al. Prediction of chronic kidney disease progression used by calcineurin inhibitor concentration and estimated glomerular filtration rate early after liver transplantation. Niger J Clin Pract. 2020;23(10):1387-94

23. Maurel P, Prémaud A, Carrier P, et al. Evaluation of longitudinal exposure to tacrolimus as a risk factor of chronic kidney disease occurrence within the first year post-liver transplantation. Transplantation. 2020 [Online ahead of print]

24. Zitta S, Schaffellner S, Gutschi J, et al. The effect of mammalian target of rapamycin versus calcineurin inhibitor-based immunosuppression on measured versus estimated glomerular filtration rate after orthotopic liver transplantation. Transplantation. 2015;99(6):1250-56

25. Zhang W, Gao Y, Wang L, et al. Early acute kidney injury associated with liver transplantation: A retrospective case-control study. Med Sci Monit. 2020;26:e923864

26. Saliba F, Duvoux C, Dharancy S, et al. Early switch from tacrolimus to everolimus after liver transplantation: Outcomes at 2 years. Liver Transpl. 2019;25(12):1822-32

27. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2(8151):1033-36

28. Karkar A, Ronco C. Prescription of CRRT: A pathway to optimize therapy. Ann Intensive Care. 2020;10(1):32

29. Zou H, Hong Q, Xu G. Early versus late initiation of renal replacement therapy impacts mortality in patients with acute kidney injury post cardiac surgery: A meta-analysis. Crit Care. 2017;21(1):150

30. Buchholz BM, Fung JW, Schnitzbauer AA, et al. Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: Impact on renal function. Transplantation. 2020;104(5):1003-18

31. Guillanelli C, Baeza-Squiban A, Boisvieux-Ulrich E, et al. Effect of mineral particles containing iron on primary cultures of rabbit tracheal epithelial cells: Possible implication of oxidative stress. Environ Health Perspect. 1993;101(5):436-42

32. Jha V, García-García G, Ikéki K, et al. Chronic kidney disease: Global dimension and perspectives. Lancet. 2013;382(9888):260-72

33. Lee K, Jeon J, Kim JM, et al. Perioperative risk factors of progressive chronic kidney disease following liver transplantation: Analyses of a 10-year follow-up single-center cohort. Ann Surg Treat Res. 2020;99(1):52-62

34. Lee J, Chen J, Lee S, et al. Early acute kidney injury associated with liver transplantation: A retrospective case-control study. Med Sci Monit. 2020;26:e923864

35. Trinh E, Alam A, Chervenkov I, Cantarovich M. Impact of acute kidney injury following liver transplantation on long-term outcomes. Clin Transplant. 2017;31(1):ctr.12863

36. Zou H, Hong Q, Xu G. Early versus late initiation of renal replacement therapy impacts mortality in patients with acute kidney injury post cardiac surgery: A meta-analysis. Crit Care. 2017;21(1):150

37. Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN Randomized Clinical Trial. JAMA. 2016;315(20):2190-99

38. Gaudry S, Hajage D, Benichou N, et al. Delivered versus early initiation of renal replacement therapy for severe acute kidney injury: A systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2020;395(10235):1506-15

39. Safwan M, Gosnell J, Collins K, et al. Effects of intraoperative continuous renal replacement therapy on outcomes in liver transplantation. Transplant Proc. 2020;52(1):265-70